Skip to content

FP7H2020HORIZON

Istituto di Ricerche Farmacologiche Mario Negri

Country
ITItaly
Defence projects
0
Projects, all programmes
85
As coordinator
16
EU contribution (CORDIS)
EUR 39,287,282
Active
2008 to 2025

Projects

85 projects, newest first

Projects, newest first
ProjectProgrammeYearRoleEU contribution
CORBELCoordinated Research Infrastructures Building Enduring Life-science servicesH20202015ParticipantEUR 204,795
SECURESecondary prEvention of CardiovascUlaR disease in the Elderly trialH20202015ParticipantEUR 1,034,363
FUTURENANONEEDSFramework to respond to regulatory needs of future nanomaterials and marketsFP72014ParticipantEUR 297,128
EPITARGETTargets and biomarkers for antiepileptogenesisFP72013ParticipantEUR 806,786
PRENANOTOXPredictive toxicology of engineered nanoparticlesFP72013ParticipantEUR 222,920
NANOPUZZLESModelling properties, interactions, toxicity and environmental behaviour of engineered nanoparticlesFP72013ParticipantEUR 227,200
HOMAGEHeart OMics in AGEingFP72013ParticipantEUR 381,362
CREACTIVECollaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in EuropeFP72013CoordinatorEUR 2,310,314
SHOCKOMICSMULTISCALE APPROACH TO THE IDENTIFICATION OF MOLECULAR BIOMARKERS IN ACUTE HEART FAILURE INDUCED BY SHOCKFP72013ParticipantEUR 482,366
KidneyConnectA Gateway to European Kidney Research Resources - KidneyConnectFP72013ParticipantEUR 11,000
EURENOMICSEuropean Consortium for High-Throughput Research in Rare Kidney DiseasesFP72012ParticipantEUR 650,001
ECRANEuropean Communication on Research Awareness NeedsFP72012CoordinatorEUR 295,764
PRIORITYProteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuriaFP72012ParticipantEUR 283,830
NILVADA European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s diseaseFP72012ParticipantEUR 352,709
EUROHYP-1European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic strokeFP72012ParticipantEUR 57,795
NanoBRIDGESBuilding bridges between specialists on computational and empirical risk assessment of engineered nanomaterialsFP72012ParticipantEUR 37,800
STELLARStem-cell based therapy for kidney repairFP72012ParticipantEUR 850,960
ECRIN-IAEuropean Clinical Research Infrastructures Network - Integrating ActivityFP72012ParticipantEUR 476,681
MUSCLEANDCANCERSearch for novel molecules cross-talking between muscle and cancer with therapeutic potential against cachexia and cancerFP72012CoordinatorEUR 100,000
SEWPROFA new paradigm in drug use and human health risk assessment: Sewage profiling at the community levelFP72012ParticipantEUR 482,988

The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.

Where this comes from

EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.

Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.

Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.